BUZZ-Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment

Reuters

Nov 27

BUZZ-Australia's Imugene gains on alliance with JW <a href="https://laohu8.com/S/LENZ">Therapeutics</a> for tumour treatment

** Shares of Imugene IMU.AX rise as much as 6.2% to A$0.345, the highest since November 6

** The biotechnology company entered a strategic collaboration with JW Therapeutics 2126.HK to evaluate a novel combination therapy to treat refractory solid tumours

** Stock up for the third straight session

** Stock currently up 3.1%, bringing YTD losses to 71.2%

(Reporting by Adwitiya Srivastava in Bengaluru)

((Adwitiya.Srivastava@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2586946912"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2586946912\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2586946912?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-27 09:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586946912","market":"nz","top_or_hot":-1,"title":"BUZZ-Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Australia's Imugene gains on alliance with JW <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for tumour treatment</title></head><body><p>** Shares of Imugene <span>IMU.AX</span> rise as much as 6.2% to A$0.345, the highest since November 6</p><p>** The biotechnology company <span>entered</span> a strategic collaboration with JW Therapeutics <span>2126.HK</span> to evaluate a novel combination therapy to treat refractory solid tumours </p><p>** Stock up for the third straight session</p><p>** Stock currently up 3.1%, bringing YTD losses to 71.2%</p><p>(Reporting by Adwitiya Srivastava in Bengaluru)</p><p>((Adwitiya.Srivastava@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-27 09:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Australia's Imugene gains on alliance with JW <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for tumour treatment</title></head><body><p>** Shares of Imugene <span>IMU.AX</span> rise as much as 6.2% to A$0.345, the highest since November 6</p><p>** The biotechnology company <span>entered</span> a strategic collaboration with JW Therapeutics <span>2126.HK</span> to evaluate a novel combination therapy to treat refractory solid tumours </p><p>** Stock up for the third straight session</p><p>** Stock currently up 3.1%, bringing YTD losses to 71.2%</p><p>(Reporting by Adwitiya Srivastava in Bengaluru)</p><p>((Adwitiya.Srivastava@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251127:nL4N3X302I:1","article_id":"2586946912","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586946912","pubTimestamp":1764205483,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment** Shares of Imugene IMU.AX rise as much as 6.2% to A$0.345, the highest since November 6** The biotechnology compan","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","BK1583":"高瓴概念","IMU.AU":"IMUGENE LTD","BK1161":"生物科技","BK1574":"生物医药B类股","02126":"药明巨诺-B","BK7067":"生物科技"},"translate_title":"BUZZ-澳大利亚Imugene与JW Therapeutics结盟治疗肿瘤","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMU.AU":0.9,"02126":0.9},"content_text":"BUZZ-Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment** Shares of Imugene IMU.AX rise as much as 6.2% to A$0.345, the highest since November 6** The biotechnology company entered a strategic collaboration with JW Therapeutics 2126.HK to evaluate a novel combination therapy to treat refractory solid tumours ** Stock up for the third straight session** Stock currently up 3.1%, bringing YTD losses to 71.2%(Reporting by Adwitiya Srivastava in Bengaluru)((Adwitiya.Srivastava@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}